Evaluation de l'efficacite antihypertensive de l'isradipine SRO par enregistrement tensionnel en ambulatoire. [Evaluation of the antihypertensive efficacy of isradipine SRO as assessed by ambulatory blood pressure determination]

Détails

ID Serval
serval:BIB_719445568FD0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Evaluation de l'efficacite antihypertensive de l'isradipine SRO par enregistrement tensionnel en ambulatoire. [Evaluation of the antihypertensive efficacy of isradipine SRO as assessed by ambulatory blood pressure determination]
Périodique
Schweizerische Rundschau fur Medizin Praxis
Auteur⸱e⸱s
Waeber B., Soret P., Poget  P. N., Brunner  H. R.
ISSN
1013-2058
Statut éditorial
Publié
Date de publication
1992
Volume
81
Numéro
50
Pages
1514-1517
Langue
français
Résumé
The calcium channel blocker isradipine has become recently available in a form with delayed release (isradipine SRO). The anti-hypertensive efficacy and tolerance of this preparation at a single daily dose of 5 mg was studied in 40 patients with uncomplicated essential hypertension over a period of 6 weeks. Blood pressure during office visits decreased under Isradipine SRO from 164/105 +/- 16/7 to 144/93 +/- 12/7 mmHg (mean +/- 1 standard deviation p < 0.001). Using ambulatory blood pressure recording we could show that antihypertensive efficacy of the new galenic form persisted over 24 hours. During the day the blood pressure dropped from 150/95 +/- 13/7 to 141/91 +/- 13/7 mmHg (p < 0.001), during the night from 131/85 +/- 13/3 to 121/81 +/- 15/9 mmHg (p < 0.001). Heart-rate was not changed by treatment and the drug was well tolerated. Isradipine SRO at a single dose is thus well suited for antihypertensive treatment.
Mots-clé
AdultAgedBlood Pressure/drug effectsDelayed-Action PreparationsFemaleHumansHypertension/*drug therapy/physiopathologyIsradipine/administration & dosage/*therapeutic useMaleMiddle AgedSingle-Blind Method
Pubmed
Création de la notice
06/03/2009 12:00
Dernière modification de la notice
20/08/2019 14:30
Données d'usage